DrugPatentWatch Database Preview
JADENU SPRINKLE Drug Profile
Try a free trial
See Plans and Pricing
When do Jadenu Sprinkle patents expire, and when can generic versions of Jadenu Sprinkle launch?
Jadenu Sprinkle is a drug marketed by Novartis Pharms Corp and is included in one NDA. There is one patent protecting this drug.
This drug has forty-eight patent family members in thirty-four countries.
The generic ingredient in JADENU SPRINKLE is deferasirox. There are twenty drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the deferasirox profile page.
Summary for JADENU SPRINKLE
| International Patents: | 48 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 100 |
| Patent Applications: | 503 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for JADENU SPRINKLE |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for JADENU SPRINKLE |
| DailyMed Link: | JADENU SPRINKLE at DailyMed |
US Patents and Regulatory Information for JADENU SPRINKLE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis Pharms Corp | JADENU SPRINKLE | deferasirox | GRANULE;ORAL | 207968-001 | May 18, 2017 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Novartis Pharms Corp | JADENU SPRINKLE | deferasirox | GRANULE;ORAL | 207968-002 | May 18, 2017 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Novartis Pharms Corp | JADENU SPRINKLE | deferasirox | GRANULE;ORAL | 207968-001 | May 18, 2017 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Novartis Pharms Corp | JADENU SPRINKLE | deferasirox | GRANULE;ORAL | 207968-002 | May 18, 2017 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Novartis Pharms Corp | JADENU SPRINKLE | deferasirox | GRANULE;ORAL | 207968-003 | May 18, 2017 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Novartis Pharms Corp | JADENU SPRINKLE | deferasirox | GRANULE;ORAL | 207968-003 | May 18, 2017 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for JADENU SPRINKLE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Novartis Pharms Corp | JADENU SPRINKLE | deferasirox | GRANULE;ORAL | 207968-001 | May 18, 2017 | ➤ Sign Up | ➤ Sign Up |
| Novartis Pharms Corp | JADENU SPRINKLE | deferasirox | GRANULE;ORAL | 207968-003 | May 18, 2017 | ➤ Sign Up | ➤ Sign Up |
| Novartis Pharms Corp | JADENU SPRINKLE | deferasirox | GRANULE;ORAL | 207968-002 | May 18, 2017 | ➤ Sign Up | ➤ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for JADENU SPRINKLE
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Hungary | 226232 | ➤ Sign Up |
| Austria | 226435 | ➤ Sign Up |
| Japan | 2000507601 | ➤ Sign Up |
| Czech Republic | 291470 | ➤ Sign Up |
| Hungary | 9903111 | ➤ Sign Up |
| Cyprus | 2429 | ➤ Sign Up |
| Czech Republic | 9804272 | ➤ Sign Up |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for JADENU SPRINKLE
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0914118 | 06C0049 | France | ➤ Sign Up | PRODUCT NAME: DEFERASIROX OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE IN FRANCE: EU/1/06/356/001 DU 20060828; REGISTRATION NO/DATE AT EEC: EU/1/06/356/001 DU 20060828 |
| 0914118 | SPC/GB07/002 | United Kingdom | ➤ Sign Up | SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB07/002 GRANTED TO NOVARTIS AG IN RESPECT OF THE PRODUCT DEFERASIROX AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, ESPECIALLY 4-(3,5-BIS(2-HYDROXYPHENYL)-(1,2,4) TRIAZOL-L-YL) BENZOIC ACID, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6179 DATED 24 OCTOBER 2007 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 30 AUGUST 2021. |
| 0914118 | SPC 035/2006 | Ireland | ➤ Sign Up | SPC 035/2006: 20070528, EXPIRES: 20210827 |
| 0914118 | 290 | Finland | ➤ Sign Up | |
| 0914118 | PA2007001 | Lithuania | ➤ Sign Up | PRODUCT NAME: DEFERASIROXUM; REGISTRATION NO/DATE: EU/1/06/356/001 2006 08 28, EU/1/06/356/002 2006 08 28, EU/1/06/356/003 2006 08 28, EU/1/06/356/004 2006 08 28, EU/1/06/356/005 2006 08 28, EU/1/06/356/00 20060828 |
| 0914118 | PA2007001,C0914118 | Lithuania | ➤ Sign Up | PRODUCT NAME: DEFERASIROXUM; REGISTRATION NO/DATE: EU/1/06/356/001 2006-08-28, EU/1/06/356/002 2006-08-28, EU/1/06/356/003 2006-08-28, EU/1/06/356/004 2006-08-28, EU/1/06/356/005 2006-08-28, EU/1/06/356/00 20060828 |
| 0914118 | C00914118/01 | Switzerland | ➤ Sign Up | PRODUCT NAME: DEFERASIROX; REGISTRATION NUMBER/DATE: SWISSMEDIC 57466 03.11.2005 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
